+

WO1997037651A1 - Procede de preparation d'un medicament (trecresan) ayant une action nootrope - Google Patents

Procede de preparation d'un medicament (trecresan) ayant une action nootrope Download PDF

Info

Publication number
WO1997037651A1
WO1997037651A1 PCT/RU1996/000153 RU9600153W WO9737651A1 WO 1997037651 A1 WO1997037651 A1 WO 1997037651A1 RU 9600153 W RU9600153 W RU 9600153W WO 9737651 A1 WO9737651 A1 WO 9737651A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
mixing
ορτο
τρeκρezana
drying
Prior art date
Application number
PCT/RU1996/000153
Other languages
English (en)
Russian (ru)
Inventor
Valery Mikhailovich Dyakov
Sergei Vitalievich Loginov
Sergei Fedorovich Kovalchuk
Eduard Yakovlievich Kaplan
Original Assignee
Valery Mikhailovich Dyakov
Sergei Vitalievich Loginov
Sergei Fedorovich Kovalchuk
Eduard Yakovlievich Kaplan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valery Mikhailovich Dyakov, Sergei Vitalievich Loginov, Sergei Fedorovich Kovalchuk, Eduard Yakovlievich Kaplan filed Critical Valery Mikhailovich Dyakov
Priority to AU61420/96A priority Critical patent/AU6142096A/en
Publication of WO1997037651A1 publication Critical patent/WO1997037651A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring

Definitions

  • the invention is related to the field of medicine, medicine, and specifically for the treatment of medical devices, ⁇ . not affecting the human immune system and having an anti-oxidative effect [1].
  • Such materials are also referred to as “immunoactive” and “immunoactive”, as long as they are of great importance. up to 40 million people in our country need it.
  • osteo-oxoacetate consists in the mixture of t-iethanolamine and oupus-transcensus ⁇ ⁇ 97/37651 ⁇ / ⁇ 96 / 00153
  • krezacin Obtained by the indicated method of krezacin, it has a high biological activity.
  • the odorless krezacin is used in medicine by the name
  • the other purpose of the invention is to increase the safety of the product and to reduce the cost of the product, the stated purpose is to be avoided by the service provider
  • Heating the mixture leads to a lower temperature compared to the known solution of the temperature in the range of (45 -65] C, and cooling in the range of (5-15) "C
  • Hexane may have been replaced by hetan or fuel, which is flammable and the same temperature
  • thermocyanine is crystallized from isopropyl alcohol-hexane taken from the mixture.
  • D ⁇ lni ⁇ eln ⁇ e improvement ⁇ aches ⁇ va ⁇ e ⁇ ezana ⁇ bes ⁇ echivae ⁇ sya ⁇ edva ⁇ i ⁇ eln ⁇ y ⁇ chis ⁇ y ⁇ - ⁇ ez ⁇ siu ⁇ susn ⁇ y ⁇ isl ⁇ y ⁇ a ⁇ zhe ⁇ u ⁇ em its mixing with coal a ⁇ ivi ⁇ vannym ma ⁇ i ⁇ G-3 P ⁇ i e ⁇ m is ⁇ lzuyu ⁇ ⁇ isanny above ⁇ same ⁇ i ⁇ ⁇ lby in ⁇ uyu zalivayu ⁇ v ⁇ dny ⁇ as ⁇ v ⁇ iz ⁇ il ⁇ v ⁇ g ⁇ s ⁇ i ⁇ a (2.4 L and 0.6 L s ⁇ i ⁇ a v ⁇ dy) of ⁇ asche ⁇ a 1 ⁇ g ⁇ isl ⁇ y 3 l v ⁇ dn ⁇ g ⁇ ⁇ as ⁇ v ⁇ a s ⁇ i ⁇ a Zag ⁇ uzhayu ⁇ 0.28 ⁇ g
  • Example 1 The use of
  • ECC ischemic heart disease
  • For diagn ⁇ s ⁇ i ⁇ i is ⁇ lz ⁇ vali data e ⁇ a ⁇ di ⁇ g ⁇ a ⁇ ii, ⁇ e ⁇ a ⁇ lya ⁇ n ⁇ y g ⁇ udn ⁇ y ⁇ e ⁇ g ⁇ a ⁇ ii ⁇ lya ⁇ g ⁇ a ⁇ ii ⁇ ,
  • Treatment was carried out by administering a dose of 0, 3 g of trekrezan (0.1 g of 3 times per day) daily for a period of three weeks (20-21 days).
  • Anth-antigen 16 87 + 0, 01%.
  • a traditional method was a significant increase, compared with a group of women, which was a decrease of 11%, an increase of 2.3%, + 2 + 13%, 2 + 13%, 2 + 13% 6.8 + 2 selfish2%, early infection from 7.69% up to 3.7%
  • ⁇ yb ⁇ any ⁇ i g ⁇ u ⁇ y zhiv ⁇ ny ⁇ e ⁇ vaya g ⁇ u ⁇ a- ⁇ liniches ⁇ i zd ⁇ vye ma ⁇ a ⁇ i (12 ⁇ s ⁇ bey) v ⁇ aya g ⁇ u ⁇ a- ⁇ slablennye with phenomena gi ⁇ dinamii and leg ⁇ g ⁇ is ⁇ scheniya and anemia (4 ⁇ aviana) ⁇ e ⁇ ya g ⁇ u ⁇ a, ⁇ luchavshie mi ⁇ d ⁇ zu (0.1 mg / ⁇ g) a ⁇ la ⁇ sina ⁇ ( ⁇ ) (2 macaques and 1 pavian), used 5% of the injected product for injection and intramuscularly from the calculation (3-5-10 ⁇ mg / kg weight during the course of injection (1-4 1 weeks).
  • G-Gluten is restored, G-Gluten is oxidized,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne essentiellement la production d'un médicament ayant des propriétés nootropes, c'est à dire agissant sur le système immunitaire humain, cette production comprenant également la purification d'une préparation connue, la Crésacine (Trécrésan). Ce procédé de production comprend les étapes suivantes: mélanger du triéthanolamine avec de l'acide ortho-crésoxyacétique dans un milieu solvant polaire et en présence de carbone actif; effectuer un premier séchage du produit obtenu avant de le recristalliser à partir d'un mélange d'alcool isopropyle et d'hexane dans une proportion de 1:1; rincer le produit à l'éther; et, enfin, effectuer un second séchage. Ce procédé concerne également la purification préliminaire de l'acide ortho-crésoxyacétique, laquelle comprend les étapes suivantes: mélanger l'acide à une solution aqueuse d'alcool en présence de carbone actif; soumettre la masse de réaction obtenue à un filtrage thermique; et enfin, filtrer et séparer les cristaux précipités avant de les rincer et de les sécher.
PCT/RU1996/000153 1996-04-10 1996-06-06 Procede de preparation d'un medicament (trecresan) ayant une action nootrope WO1997037651A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61420/96A AU6142096A (en) 1996-04-10 1996-06-06 Method for producing a drug (trecresan) with nootropic activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU96106916 1996-04-10
RU96106916/14A RU2098088C1 (ru) 1996-04-10 1996-04-10 Способ получения лекарственного средства (трекрезана) с иммунотропным действием

Publications (1)

Publication Number Publication Date
WO1997037651A1 true WO1997037651A1 (fr) 1997-10-16

Family

ID=20179127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1996/000153 WO1997037651A1 (fr) 1996-04-10 1996-06-06 Procede de preparation d'un medicament (trecresan) ayant une action nootrope

Country Status (3)

Country Link
AU (1) AU6142096A (fr)
RU (1) RU2098088C1 (fr)
WO (1) WO1997037651A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429833C1 (ru) * 2010-09-08 2011-09-27 Максуд Мухамеджанович Расулов Средство, повышающее активность кислой липазы тромбоцитов
RU2486894C1 (ru) * 2012-05-11 2013-07-10 Максуд Мухамеджанович Расулов Средство, повышающее уровень лактоферрина в организме
RU2486895C1 (ru) * 2012-05-11 2013-07-10 Максуд Мухамеджанович Расулов Средство, модулирующее концентрацию ферритина в сыворотке крови

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197962C2 (ru) * 2000-08-28 2003-02-10 Иркутская государственная сельскохозяйственная академия Лекарственное средство для лечения железодефицитной анемии
RU2195936C2 (ru) * 2000-11-17 2003-01-10 Щекина Ирина Анатольевна Способ защиты печени от ксенобиотиков в эксперименте
RU2224512C1 (ru) * 2003-03-27 2004-02-27 Лимонов Виктор Львович Иммуномодулятор
RU2245142C1 (ru) * 2003-07-14 2005-01-27 Лимонов Виктор Львович Иммуномодулятор
RU2253445C1 (ru) * 2003-12-02 2005-06-10 Лимонов Виктор Львович Иммуномодулятор
RU2253444C1 (ru) * 2003-12-02 2005-06-10 Лимонов Виктор Львович Иммуномодулятор
RU2268879C1 (ru) * 2004-05-12 2006-01-27 Анатолий Александрович Ермаков Способ получения трис-(2-оксиэтил)аммоний-о-крезоксиацетата
RU2407526C1 (ru) * 2009-07-27 2010-12-27 Максуд Мухамеджанович Расулов СРЕДСТВО, ПОВЫШАЮЩЕЕ АКТИВНОСТЬ СУММАРНОЙ ТРИПТОФАНИЛ-тPHK-СИНТЕТАЗЫ
RU2429832C1 (ru) * 2010-04-01 2011-09-27 Максуд Мухамеджанович Расулов Применение трекрезана для лечения больных артериальной гипертонией и ожирением
RU2445087C1 (ru) * 2010-12-22 2012-03-20 Максуд Мухамеджанович Расулов Средство, модулирующее активность кислой фосфолипазы а1
RU2444357C1 (ru) * 2010-12-22 2012-03-10 Максуд Мухамеджанович Расулов Средство, снижающее активность холестеролэстеразы
RU2564114C1 (ru) * 2014-05-22 2015-09-27 Общество с ограниченной ответственностью "Фарматрикс" (ООО "Фарматрикс") Индуктор il-12 и il-1a

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2432392A1 (de) * 1973-07-05 1975-01-30 Ir I Orch Chimii Sib Otdel Aka Tris-(2-hydroxyaethyl)-ammonium-orthokresoxyazetat und verfahren zu dessen herstellung
US4283419A (en) * 1978-11-01 1981-08-11 Voronkov Mikhail G Preparation for raising the fertility of animals
AU519263B2 (en) * 1978-11-09 1981-11-19 Irkutsky Ioksoans Preparation for rasing fertility in animals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2432392A1 (de) * 1973-07-05 1975-01-30 Ir I Orch Chimii Sib Otdel Aka Tris-(2-hydroxyaethyl)-ammonium-orthokresoxyazetat und verfahren zu dessen herstellung
FR2235681A1 (fr) * 1973-07-05 1975-01-31 Ir I Orch
US4283419A (en) * 1978-11-01 1981-08-11 Voronkov Mikhail G Preparation for raising the fertility of animals
AU519263B2 (en) * 1978-11-09 1981-11-19 Irkutsky Ioksoans Preparation for rasing fertility in animals

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429833C1 (ru) * 2010-09-08 2011-09-27 Максуд Мухамеджанович Расулов Средство, повышающее активность кислой липазы тромбоцитов
RU2486894C1 (ru) * 2012-05-11 2013-07-10 Максуд Мухамеджанович Расулов Средство, повышающее уровень лактоферрина в организме
RU2486895C1 (ru) * 2012-05-11 2013-07-10 Максуд Мухамеджанович Расулов Средство, модулирующее концентрацию ферритина в сыворотке крови

Also Published As

Publication number Publication date
RU2098088C1 (ru) 1997-12-10
AU6142096A (en) 1997-10-29

Similar Documents

Publication Publication Date Title
WO1997037651A1 (fr) Procede de preparation d'un medicament (trecresan) ayant une action nootrope
Khory et al. Materica Medica of India and Their Therapeutics
KR100189144B1 (ko) 신규 생리 활성 물질
US10265345B2 (en) Use of extracts from rabbit skin inflamed by vaccinia virus for the manufacture of a medicament for the treatment of acute cerebrovascular disease
WO2005102372A1 (fr) Compositions de correction de changements du systeme endocrinien humain dus a l'age et procede de fabrication d'une forme pharmaceutique sur la base de ces compositions
CN111820314A (zh) 一种利用鹿血多肽和枸杞多糖制备的抗疲劳保健品
WO2007071334A2 (fr) Extraits de phaseolus vulgaris, leur utilisation, et préparations les contenant
DE3319575A1 (de) Therapeutisch wirksame zusammensetzungen, nahrungsmittel und getraenke
EP1757299A1 (fr) Complexes de fer III pour traiter les manques de fer en patients avec la maladie intestinale inflammatoire
WO2003072124A1 (fr) Methode d'induction de differentiation cellulaire
BRODIE et al. Acute hepatic porphyrias
CN101633945A (zh) 一种含vvyp肽的珠肽粉的制备方法
JPH07285881A (ja) アルコール代謝促進剤
RU2377005C1 (ru) Способ лечения желудочно-кишечных болезней у телят
DE60037197T2 (de) Verwendung funktioneller oraler präparate
WO2004064849A1 (fr) Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale
US6884421B2 (en) Pharmaceutical composition for diabetic nephropathy
WO2002043740A1 (fr) Procede de fabrication d'un produit antiviral immunotropique
WO2002092110A1 (fr) Nouvelle utilisation de polyphenol de plantes naturelles et de medicaments et/ou de produits medicaux contenant du polyphenol de plantes naturelles
WO1997045530A1 (fr) Utilisation de souches de streptococcus faecium et composition a base de ces souches
CN117338869B (zh) 一种用于治疗便秘和改善皮肤暗沉的中药胶囊及其制备方法
JPH08205807A (ja) 熟成濃縮無口臭大蒜液の製造方法
JP3764496B2 (ja) アルコール性肝機能障害抑制剤
US3020204A (en) Process for preparing augmentative intrinsic factor concentrate
STUTZER et al. Physiological Chemistry.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97536105

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载